Nutra Pharma has made changes in payment terms to its over-the-counter (OTC) pain reliever Cobroxin oral spray distribution agreement with XenaCare.

Nutra Pharma’s Cobroxin, currently available as an oral spray, is a treatment for migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Earlier, Nutra Pharma has entered into an agreement with XenaCare in 2009 for the distribution of Cobroxin in the US.

Nutra Pharma chairman and CEO Rik Deitsch said that in light of XenaCare’s recently launched television advertising campaign, they have decided to continue their relationship with XenaCare to help them build the Cobroxin brand.

“As XenaCare’s advertising continues, we remain optimistic that Cobroxin will become better known among consumers. XenaCare’s management has already informed us of improving sales exposure due to their advertising campaign. We look forward to working closely with XenaCare as they continue their ongoing advertising support for Cobroxin,” Deitsch said.